New drug combo targets tough prostate cancer in understudied groups
NCT ID NCT06392841
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 15 times
Summary
This study was designed to test a combination of two drugs (niraparib and abiraterone plus prednisone) in Hispanic/Latino and Black patients with metastatic hormone-sensitive prostate cancer that has certain gene mutations. The goal was to see if the treatment could lower PSA levels significantly after 24 weeks. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.